LXEO vs WFC · $147.7M cap vs P/E 15, rev $22.62B
Lexeo Therapeutics, Inc. Common Stock (LXEO) versus Wells Fargo & Company (WFC) — a side-by-side from cached financials, not a winner call.
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a biotechnology company listed on US.
Wells Fargo & Company (WFC) is a banks - diversified company listed on US. It is led by Charlie Scharf.
LXEO does not have a complete income-statement cache yet.
Latest reported WFC revenue for 2026-06-30 was $22.62B. Net income was $6.41B. Revenue was up 5.5% from 2026-03-31 to 2026-06-30. WFC currently screens at market cap $272.05B and trailing P/E 15.0.
LXEO currently screens at market cap $147.7M. WFC currently screens at market cap $272.05B and trailing P/E 15.0.
Not investment advice. Open the LXEO and WFC stock pages for the full models.
Not investment advice.